Actinium Pharmaceuticals (ATNM) Interest Expenses (2010 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Interest Expenses of $202000.0 for Q1 2026, up 29.49% year-over-year from $156000.0 in Q1 2025, and up 16.09% quarter-over-quarter from $174000.0 in Q4 2025.
Actinium Pharmaceuticals (ATNM) Interest Expenses (2010 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Interest Expenses for 17 consecutive years, with $202000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 29.49% year-over-year to $202000.0; the TTM figure through Mar 2026 stood at $688000.0 (up 11.87% YoY), while the FY2025 annual figure was $116.1 million, up 14.23% from the prior year.
- Interest Expenses improved to $202000.0 in Q1 2026 per ATNM's latest filing, from $174000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $12.5 million in Q1 2024 and bottomed at $2000.0 in Q2 2023.
- Historically, Interest Expenses has averaged $1.9 million across 5 years, with a median of $156000.0 in 2024.
- Annual changes were most pronounced in 2024 — Interest Expenses soared 522950.0% — and 2025, when it tumbled 99.36%.
- Actinium Pharmaceuticals' Interest Expenses stood at $50000.0 in 2022, then jumped by 206.0% to $153000.0 in 2023, then gained by 1.96% to $156000.0 in 2024, then advanced by 11.54% to $174000.0 in 2025, then increased by 16.09% to $202000.0 in 2026.
- Business Quant data shows ATNM's Interest Expenses at $202000.0 in Q1 2026, $174000.0 in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.53 Mn |
| Jun 30, 2026 | 1.53 Mn |
| Mar 31, 2026 | 202,000.00 |
| Mar 31, 2026 | 202,000.00 |
| Dec 31, 2025 | 174,000.00 |
| Dec 31, 2025 | 174,000.00 |
| Sep 30, 2025 | 1.18 Mn |
| Sep 30, 2025 | 1.18 Mn |
| Jun 30, 2025 | 67,000.00 |
| Jun 30, 2025 | 67,000.00 |
| Mar 31, 2025 | 156,000.00 |
| Mar 31, 2025 | 156,000.00 |
| Dec 31, 2024 | 156,000.00 |
| Dec 31, 2024 | 156,000.00 |
| Sep 30, 2024 | 121,000.00 |
| Sep 30, 2024 | 121,000.00 |
| Jun 30, 2024 | 10.46 Mn |
| Jun 30, 2024 | 10.46 Mn |
| Mar 31, 2024 | 12.55 Mn |
| Mar 31, 2024 | 12.55 Mn |